Personalized DNA Neoantigen Vaccine & Pembrolizumab in Advanced Hepatocellular Carcinoma
Time: 4:10 pm
day: Day One
Details:
- Updates on clinical response data from GNOS-PV02 Phase 1b/2a clinical trial in 2L advanced HCC
- Highlighting pharmacodynamic and biomarker data from personalized DNA cancer vaccine in combination with Pembrolizumab
- What are critical factors for clinical translation of personalized therapies?
